SomaLogic announces deployment of SOMAscan® assay to Beth Israel Deaconess Medical Center (BIDMC)
SomaLogic announced today that the Beth Israel Deaconess Medical Center in Boston, MA, is the latest academic center to deploy the SOMAscan assay in support of the protein biomarker discovery and development efforts of its research community. The SOMAscan assay will be performed under the leadership of Towia Libermann, PhD, Director of the BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center and the Dana–Farber/Harvard Cancer Center (DF/HCC) Cancer Proteomics Core.
“We are delighted to partner with Beth Israel Deaconess Medical Center, a world-class medical research center and teaching hospital of Harvard Medical School, to expand the availability of the SOMAscan assay to BIDMC’s incredible scientists and to investigators at other academic centers in Boston,” said Byron Hewett, Chief Executive Officer of SomaLogic. “Under the strong leadership of Dr. Libermann, we believe that this expanded access will lead to many new breakthrough discoveries in biology and medicine.”
Compared to other current proteomic technologies, SomaLogic provides researchers with unprecedented power for protein biomarker discovery, diagnostics development and pharmaceutical discovery and development. SOMAmer reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates over 1,300 different SOMAmer reagents, can efficiently, accurately and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.
BIDMC is the tenth named academic center to deploy the SOMAscan assay “in-house.” SomaLogic is continuing efforts to make its technology more easily available to researchers worldwide, and will announce additional new SOMAscan assay sites over the next several months.